VacZine Analytics  
MarketVIEW: Nipah virus vaccines

Published: November 2018

Nipah virus infection (NiV) is caused by Nipah Virus, an RNA virus and member of the Paramyxoviridae family (genus Henipavirus). The virus, first isolated in 1999 following an outbreak of encephalitis and acute respiratory illness in Malaysia and Singapore, has registered around 600 infections to date but has pandemic potential according to the World Health Organisation. NiV infected patients (all ages susceptible) usually present with fever, headache, myalgia, vomiting and sore throat. Some patients develop more severe symptoms such as atypical pneumonia and severe respiratory problems, which can be fatal (CFR >70%). Fruit bats of the Pteropus genus are the natural hosts of NiV which can be transmitted to humans via pigs as an intermediate host, but human-to-human transmission (especially nosocomial) has also been documented in notable India and Bangladesh outbreaks.

This MarketVIEW product is a comprehensive Executive Presentation (~105 slides) and MS-Excel forecast model which investigates the commercial potential of a putative Nipah virus vaccine in all relevant target groups (preventative and emergency scenarios) to 2035. The potential of public (stockpile) and potential private markets are explored. There is a detailed case study analysis of Ebola vaccine procurement/deployment to serve as guidance with all assumptions clearly outlined. A thorough review of current disease background/epidemiology and R&D competitive environment are also included. This product is ideally suited to organisations wishing to quantify the Nipah virus vaccine opportunity.

THIS PRODUCT IS A SUMMARY PRESENTATION (105 slides, .pdf form) + FORECAST MODEL (.xls)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV081 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2018 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains